A French consortium led by INRA, in collaboration with INSERM, the Universities of Lyon and Clermont Auvergne, Lyon Civil Hospitals and the Human Nutrition Research Centres (CRNH) of Rhône-Alpes and Auvergne, have now demonstrated that consuming certain lipids present naturally in dairy products (called “polar lipids”) could reduce the cardiovascular risk in overweight postmenopausal women by lowering their blood levels of LDL-cholesterol (“bad” cholesterol) and triglycerides. To reach this conclusion, the scientists included a cream cheese enriched in buttermilk polar lipids in the daily diet of volunteers for a period of one month. They were able to reveal certain mechanisms in the gut that might explain the effects observed. These natural dietary compounds could therefore form part of a new nutritional strategy designed to reduce the cardiovascular risk in vulnerable populations. This work was published on 12 June in Gut.
Dairy products contain a wide variety of lipids, both triglycerides and polar lipids, the latter being specific lipids that naturally stabilise fat droplets and are notably found in cream and buttermilk. Polar lipids play a crucial physiological role as they are essential components of cell membranes. Preliminary experiments in rodents had revealed the beneficial effects of milk polar lipids on liver metabolism and the regulation of blood cholesterol levels. However, until now, these effects had never been demonstrated in human volunteers with a high cardiovascular risk.
The scientists then sought to unravel the mechanism underlying this effect. Their complementary studies suggested that certain milk polar lipids and cholesterol (of both dietary and endogenous origin) may form a complex in the small intestine that cannot be absorbed by the gut and is ultimately excreted in the stools.
This work was carried out in the context of the ANR VALOBAB project (2012-2016) coordinated by Marie-Caroline Michalski, INRA Research Director in the Université Lyon 1-INRA-INSERM-INSA de Lyon Joint Research Unit for Cardiovascular, Metabolism, Diabetes and Nutrition (CarMeN). The project also involved the French Dairy Interbranch Organisation (CNIEL) and six other research laboratories and centres: CarMeN in Lyon, CRNH Rhône-Alpes, the Joint Research Unit for Human Nutrition and the INRA-UCA Joint Research Unit for Microbiology, the Digestive Environment and Health, both in Clermont-Ferrand, CRNH Auvergne, the INRA-AgroCampus Ouest Joint Research Unit for the Science and Technology of Milk and Eggs in Rennes, ENILIA (Surgères, with the participation of ACTALIA Produits Laitiers and Philolao) and ITERG (Bordeaux). The VALOBAB project received support from the ANR (ANR-11-ALID-007) and was accredited by the VALORIAL (Tomorrow’s Foods) Competiveness Cluster.
This clinical study, sponsored by Lyon Civil Hospitals, was also funded by PHRC-I VALOBAB.
Circulating tumor cells use the blood and lymphatic networks to disseminate within the body, forming metastases distant from the primary tumor. Inserm researcher Jacky Goetz and his Tumor Biomechanics team at the Molecular ImmunoRheumatology laboratory (Inserm/Université de Strasbourg) have helped to show ...
Suite aux cas de thromboses survenus après la vaccination contre la Covid-19, l’équipe du Pr David Smadja, professeur d’hématologie d’Université de Paris, membre du service d’hématologie de l’hôpital européen Georges-Pompidou AP-HP et directeur d’une équipe de l’unité Inserm 1140 (Université de Paris) a ...
Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay.
Vors C. et al. Gut. DOI: 10.1136/gutjnl-2018-318155